Breast cancer patient-derived organoids for the investigation of patient-specific tumour evolution

被引:0
作者
Mazzucchelli, Serena [1 ]
Signati, Lorena [1 ]
Messa, Letizia [2 ,4 ,5 ]
Franceschini, Alma [6 ]
Bonizzi, Arianna [3 ]
Castagnoli, Lorenzo [6 ]
Gasparini, Patrizia [7 ]
Consolandi, Clarissa [8 ]
Mangano, Eleonora [8 ]
Pelucchi, Paride [8 ]
Cifola, Ingrid [8 ]
Camboni, Tania [8 ]
Severgnini, Marco [8 ]
Villani, Laura [3 ]
Tagliaferri, Barbara [3 ]
Carelli, Stephana [4 ,5 ]
Pupa, Serenella M. [6 ]
Cereda, Cristina [5 ]
Corsi, Fabio [1 ,3 ]
机构
[1] Univ Milan, Dipartimento Sci Biomed & Clin, Via GB Grassi 74, I-20157 Milan, Italy
[2] Politecn Milan, Dept Elect Informat & Bioengn DEIB, I-20133 Milan, Italy
[3] Ist Clin Sci Maugeri IRCCS, I-27100 Pavia, Italy
[4] Univ Milan, Pediat Res Ctr Romeo & Enrica Invernizzi, I-20157 Milan, Italy
[5] Buzzi Childrens Hosp, Ctr Funct Genom & Rare Dis, I-20154 Milan, Italy
[6] Fdn IRCCS Ist Nazl Tumori Milano, Dept Expt Oncol, Microenvironm & Biomarkers Solid Tumors, I-20133 Milan, Italy
[7] Fdn IRCCS Ist Nazl Tumori Milano, Dept Expt Oncol, Epigen & Biomarkers Solid Tumors, I-20133 Milan, Italy
[8] Natl Res Council ITB CNR, Inst Biomed Technol, Via F lli Cervi 93, I-20054 Segrate, Italy
关键词
Breast cancer; Patient-derived organoids; Tumour evolution; TRASTUZUMAB; EXPRESSION; COMPLEX; CELLS;
D O I
10.1186/s12935-024-03375-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundA reliable preclinical model of patient-derived organoids (PDOs) was developed in a case study of a 69-year-old woman diagnosed with breast cancer (BC) to investigate the tumour evolution before and after neoadjuvant chemotherapy and surgery. The results were achieved due to the development of PDOs from tissues collected before (O-PRE) and after (O-POST) treatment.MethodsPDO cultures were characterized by histology, immunohistochemistry (IHC), transmission electron microscopy (TEM), scanning electron microscopy (SEM), confocal microscopy, flow cytometry, real-time PCR, bulk RNA-seq, single-cell RNA sequencing (scRNA-seq) and drug screening.ResultsBoth PDO cultures recapitulated the histological and molecular profiles of the original tissues, and they showed typical mammary gland organization, confirming their reliability as a personalized in vitro model. Compared with O-PRE, O-POST had a greater proliferation rate with a significant increase in the Ki67 proliferation index. Moreover O-POST exhibited a more stem-like and aggressive phenotype, with increases in the CD24low/CD44low and EPCAMlow/CD49fhigh cell populations characterized by increased tumour initiation potential and multipotency and metastatic potential in invasive lobular carcinoma. Analysis of ErbB receptor expression indicated a decrease in HER-2 expression coupled with an increase in EGFR expression in O-POST. In this context, deregulation of the PI3K/Akt signalling pathway was assessed by transcriptomic analysis, confirming the altered transcriptional profile. Finally, transcriptomic single-cell analysis identified 11 cell type clusters, highlighting the selection of the luminal component and the decrease in the number of Epithelial-mesenchymal transition cell types in O-POST.ConclusionNeoadjuvant treatment contributed to the enrichment of cell populations with luminal phenotypes that were more resistant to chemotherapy in O-POST. PDOs represent an excellent 3D cell model for assessing disease evolution.
引用
收藏
页数:18
相关论文
共 44 条
  • [1] Albanell J, 2003, ADV EXP MED BIOL, V532, P253
  • [2] Basal Breast Cancer: A Complex and Deadly Molecular Subtype
    Bertucci, F.
    Finetti, P.
    Birnbaum, D.
    [J]. CURRENT MOLECULAR MEDICINE, 2012, 12 (01) : 96 - 110
  • [3] A single-cell atlas of the healthy breast tissues reveals clinically relevant clusters of breast epithelial cells
    Bhat-Nakshatri, Poornima
    Gao, Hongyu
    Sheng, Liu
    McGuire, Patrick C.
    Xuei, Xiaoling
    Wan, Jun
    Liu, Yunlong
    Althouse, Sandra K.
    Colter, Austyn
    Sandusky, George
    Stomiolo, Anna Maria
    Nakshatri, Harikrishna
    [J]. CELL REPORTS MEDICINE, 2021, 2 (03)
  • [4] Integrating single-cell transcriptomic data across different conditions, technologies, and species
    Butler, Andrew
    Hoffman, Paul
    Smibert, Peter
    Papalexi, Efthymia
    Satija, Rahul
    [J]. NATURE BIOTECHNOLOGY, 2018, 36 (05) : 411 - +
  • [5] BDP1 Alterations Correlate with Clinical Outcomes in Breast Cancer
    Cabarcas-Petroski, Stephanie
    Schramm, Laura
    [J]. CANCERS, 2022, 14 (07)
  • [6] Response-based molecular subtyping-emergence of the third generation of breast cancer subtypes
    Denkert, Carsten
    Loibl, Sibylle
    [J]. CANCER CELL, 2022, 40 (06) : 592 - 594
  • [7] Establishment of patient-derived cancer organoids for drug-screening applications
    Driehuis, Else
    Kretzschmar, Kai
    Clevers, Hans
    [J]. NATURE PROTOCOLS, 2020, 15 (10) : 3380 - 3409
  • [8] Pancreatic cancer organoids recapitulate disease and allow personalized drug screening
    Driehuis, Else
    van Hoeck, Arne
    Moore, Kat
    Kolders, Sigrid
    Francies, Hayley E.
    Gulersonmez, M. Can
    Stigter, Edwin C. A.
    Burgering, Boudewijn
    Geurts, Veerle
    Gracanin, Ana
    Bounova, Gergana
    Morsink, Folkert H.
    Vries, Robert
    Boj, Sylvia
    van Es, Johan
    Offerhaus, G. Johan A.
    Kranenburg, Onno
    Garnett, Mathew J.
    Wessels, Lodewyk
    Cuppen, Edwin
    Brosens, Lodewijk A. A.
    Clevers, Hans
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2019, 116 (52) : 26580 - 26590
  • [9] Personalized Cancer Medicine: An Organoid Approach
    Es, Hamidreza Aboulkheyr
    Montazeri, Leila
    Aref, Amir Reza
    Vosough, Massoud
    Baharvand, Hossein
    [J]. TRENDS IN BIOTECHNOLOGY, 2018, 36 (04) : 358 - 371
  • [10] Germain Pierre-Luc, 2021, F1000Res, V10, P979, DOI 10.12688/f1000research.73600.1